Foresight Diagnostics' approach for the earlier detection of cancer recurrence pulls in nearly $59M
In a crowded field of cancer diagnostics companies looking to detect relapses earlier, Foresight Diagnostics thinks it has a more sensitive approach. On Thursday, it received more than $58 million to test the theory.
Even after successful cancer treatment, regular imaging can be a source of anxiety for patients — and a clear scan doesn’t necessarily mean a patient won’t relapse later on.
“I work with a number of physicians and they recurrently say what they hate the most is telling a patient, ‘As far as I can tell you’re cured, but the statistics tell us that over the next two years you have X percent chance of relapse,’” Foresight CEO and co-founder Jake Chabon said.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters